补肺益肾法治疗支气管哮喘缓解期的系统评价  

Systematic Review of Bufei Yishen Method for the Treatment of Bronchial Asthma in Remission Stage

作　　者：王琳君 李耀辉 李哲[3] 刘伊莎 刘砺寒 钟珍 WANG Linjun;LI Yaohui;LI Zhe;LIU Yisha;LIU Lihan;ZHONG Zhen(The First Clinical Medical College,College of Clinical Medicine,Shaanxi University of Chinese Medicine,Shaanxi Xianyang 712046,China;Dept.of Pulmonary Disease,Shaanxi Provincial Hospital of Chinese Medicine,Xi’an 710000,China;Development Research Center,China Academy of Chinese Medical Sciences,Beijing 100700,China)

机构地区：[1]陕西中医药大学第一临床医学院,陕西咸阳712046 [2]陕西省中医医院肺病科,西安710000 [3]中国中医科学院发展研究中心,北京100700

出　　处：《中国医院用药评价与分析》2022年第4期468-474,共7页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：陕西省科学技术厅项目(No.2020SF-351)。

摘　　要：目的:系统评价补肺益肾法治疗支气管哮喘缓解期的疗效和安全性。方法:通过对中国知网、万方数据库、维普数据库、PubMed和the Cochrane Library等数据库进行检索,收集补肺益肾法治疗支气管哮喘缓解期的随机对照试验,检索时限为建库至2021年12月,2名评价员分别对检索出的文献进行筛选并提取有效数据,采用Cochrane软件评价文献质量,采用RevMan 5.3软件进行Meta分析。结果:最终纳入15项随机对照试验,共1305例患者。Meta分析结果显示,补肺益肾法在改善支气管哮喘缓解期的临床有效率、中医证候积分、肺功能、白细胞介素(IL)4和IL-8等结局指标方面优于单纯西医常规治疗,差异均有统计学意义(P<0.05);补肺益肾法的不良反应发生情况与单纯西医常规治疗相似,且不良反应较少,具有较好的安全性;但目前尚无确切证据表明补肺益肾法在改善血清NO浓度、IL-5水平方面优于单纯西医常规治疗。结论:研究结果提示,在支气管哮喘缓解期的治疗中使用补肺益肾法优于单纯西医常规治疗,具有一定的可行性和应用价值,但由于临床研究证据质量偏低,有必要进行高质量的随机对照试验进一步验证。OBJECTIVE:To systematically review the efficacy and safety of Bufei Yishen method in the treatment of bronchial asthma in remission stage.METHODS:CNKI,Wanfang Data,VIP,PubMed and the Cochrane Library database were retrieved to collect the randomized controlled trials of Bufei Yishen method in the treatment of bronchial asthma in remission stage.The retrieval time was from the establishment of the database to Dec.2021.Two evaluators screened the retrieved literature and extracted valid data respectively.Cochrane software was used to evaluate the literature quality,and RevMan 5.3 software was used for Meta-analysis.RESULTS:Fifteen randomized controlled trials with a total of 1305 patients were ultimately included.Meta-analysis results showed that Bufei Yishen method was better than conventional western medicine alone in improving the clinical efficiency,traditional Chinese medicine syndrome score,lung function,interleukin(IL)-4 and IL-8 and other outcome indicators of bronchial asthma in remission stage,the differences were statistically significant(P<0.05).The incidence of adverse drug reactions of Bufei Yishen method was similar to that of conventional western medicine,and the incidence of adverse drug reactions of Bufei Yishen method was lower with higher safety.There was no definite evidence that Bufei Yishen method was superior to conventional western medicine in improving serum NO concentration and IL-5 level.CONCLUSIONS:The results suggest that the application of Bufei Yishen method in the treatment of bronchial asthma in remission stage is superior to conventional western medicine,and has certain feasibility and application value.However,due to the low quality of clinical evidence,it is necessary to perform high-quality randomized controlled trials for further verification.

关 键 词：支气管哮喘 缓解期 补肺益肾法 META分析 

分 类 号：R932[医药卫生—生药学]